Clinical trials: Anginal Pain
Stable Angina
CYP2C19 Gene Alteration and Thienopyridine Resistance in Percutaneous Coronary Intervention Study
Dual antiplatelet therapy with aspirin and thienopyridines decreases the rate of stent thrombosis in patients undergoing percutaneous coronary intervention (PCI).
- Trial name
- CALDERA-PCI (NCT00876512)
- Where
- Japan
- Volunteers
- 104 people
- Sponsor
- Kumamoto University
Coronary Microvascular Dysfunction, Coronary Microvascular Disease
Absolute Flow for Ischemia With No Obstructive Coronary Arteries
The main objective is to prospectively validate the capacity of continuous thermodilution coronary flow reserve (CFRflow) as a predictor of the presence of angina measured by SAQ7 in patients with INOCA at 3 months.
- Conditions
- Coronary Microvascular Dysfunction, Coronary Microvascular Disease, Angina, Stable
- Trial name
- AF-INOCA (NCT05825339)
- Testing
- Coronary Flow Reserve
- Where
- 6 sites in Spain
- Volunteers
- 121 people
- Sponsor
- Spanish Society of Cardiology
Angina Pectoris, Unstable Angina
Pilot Study of Hemoglobin Based Oxygen Therapeutics in Elective Coronary Revascularization
The purpose of this study is to assess the safety and feasibility of a novel oxygen carrying solution, HBOC-201, in the setting of PCI for Acute Coronary Syndromes from randomization til hospital discharge.
- Conditions
- Angina Pectoris, Unstable Angina, Myocardial Infarction
- Trial name
- NCT00317512
- Testing
- Percutaneous Coronary Revascularization, Hemoglobin-Based Oxygen Carrier-201 (HBOC-201), Voluven
- Where
- 6 sites in Belgium, Germany and 1 more
- Volunteers
- 45 people
- Sponsor
- Biopure Corporation
ANOCA - Angina With Non-obstructive Coronary Arteries, Coronary Microvascular Dysfunction (CMD)
Nebivolol ANOCA Treatment Randomized Trial
To determine the effectiveness of the beta-blocker nebivolol in controlling symptoms and improving the quality of life in patients with angina and coronary microvascular dysfunction.
- Trial name
- MOTORS (NCT06755801)
- Testing
- Nevibolol
- Volunteers
- 150 people
- Sponsor
- Spanish Society of Cardiology
Coronary Artery Disease, Asthma
Comparison of Dobutamine and Regadenoson Stress Cardiac Magnetic Resonance (MR)
The goal of this research is to determine the utility of Regadenoson (Lexiscan)for use as an imaging agent with cardiac MR. If found useful, it will help us establish a protocol for regadenoson stress MR perfusion (Regadenoson…
- Conditions
- Coronary Artery Disease, Asthma, Chronic Obstructive Pulmonary Disease (COPD), Angina
- Trial name
- NCT00763035
- Testing
- Regadenoson, Dobutamine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Wake Forest University Health Sciences
Unstable Angina
PROTECT-TIMI 30 Trial
The primary purpose of this study was to compare the efficacy and safety of bivalirudin to eptifibatide (with or without unfractionated heparin or enoxaparin)given to subjects at high risk for heart attack and other…
- Trial name
- NCT00250471
- Testing
- Percutaneous Coronary Intervention (PCI)
- Volunteers
- 900 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Coronary Artery Disease, Coronary Heart Disease
Comparison of the Angiographic Result of the Orsiro Hybrid Stent With Resolute Integrity Stent
The purpose of this multicenter, randomized, open label, parallel arm study whether the newest 3rd generation stent - Orsiro hybrid sirolimus-eluting stent is noninferior to the newest 2nd generation stent - Resolute Integrity…
- Conditions
- Coronary Artery Disease, Coronary Heart Disease, Stable Angina, Unstable Angina
- Trial name
- ORIENT (NCT01826552)
- Testing
- Osiro Hybrid Drug-Eluting Stent, Resolute Integrity
- Where
- 8 sites in South Korea
- Volunteers
- 372 people
- Sponsor
- Seoul National University Bundang Hospital
Coronary Heart Disease, Stable Angina Pectoris
Heterogeneity of Neointimal Healing Following Biodegradable-polymer Drug-Eluting Coronary Stent Implantation
The objective of this study is a comparative evaluation of Orsiro stent and of Resolute Integrity stent in terms of the extent of neointima formation at 4 months after implantation using optical coherence tomography (OCT).
- Conditions
- Coronary Heart Disease, Stable Angina Pectoris, Silent Myocardial Ischemia
- Trial name
- Healing (NCT04465669)
- Testing
- Orsiro stents, Resolute Integrity® stents
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- Tomsk National Research Medical Center of the Russian Academy of Sciences
Acute Coronary Syndromes, STEMI
Early Single Antiplatelet Therapy After IVUS-Guided PCI in Acute Coronary Syndrome
This is a prospective, open-label, multicenter, randomized, phase IV clinical trial designed to evaluate the safety and efficacy of early aspirin discontinuation followed by potent P2Y12 inhibitor monotherapy after intravascular…
- Conditions
- Acute Coronary Syndromes, STEMI, NSTEMI, Unstable Angina
- Trial name
- SAPT-ACS (NCT07684742)
- Testing
- Early P2Y12 Inhibitor Monotherapy, Standard Dual Antiplatelet Therapy
- Where
- South Korea
- Volunteers
- 1,900 people
- Sponsor
- Gyeongsang National University Hospital
Heart Diseases, Cardiovascular Diseases
Acute Cardiac Ischemia in Women in the ACI/TIPI Trial
To conduct a series of five inter-related studies on acute cardiac ischemia (ACI) in women.
- Conditions
- Heart Diseases, Cardiovascular Diseases, Angina Pectoris, Myocardial Ischemia
- Trial name
- NCT00005701
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Cardiovascular Diseases, Coronary Disease
Multicenter Study of Silent Myocardial Ischemia (MSSMI)
To determine if silent myocardial ischemia was associated with an increased risk of cardiac mortality and morbidity during a one to three year follow-up in patients with coronary heart disease.
- Conditions
- Cardiovascular Diseases, Coronary Disease, Myocardial Ischemia, Heart Diseases
- Trial name
- NCT00005216
- Sponsor
- University of Rochester
Refractory Angina Pectoris
Effect of Daily Remote Ischemic Conditioning on the Life Quality of Refractory Angina Pectoris Patients
The purpose is to test whether daily ischemic conditioning of the arms over 30 days could reduce the frequency and severity of angina pectoris and improve the life quality of refractory angina pectoris patients.
- Trial name
- D-RIC-RAP (NCT02499250)
- Testing
- remote ischemic conditioning (TDFT-12-A2), Optimal medical treatment
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Navy General Hospital, Beijing
Coronary Syndrome
WILL lOWer Dose Aspirin be Better With Rivaroxaban in Patients With Chronic Coronary Syndromes?
The trial is a pharmacodynamic study to determine the effect of a novel regimen of aspirin 20 mg BD plus rivaroxaban 2.5 mg BD on haemostasis, fibrin clot dynamics, inflammatory markers, platelet function and arachidonic acid…
- Trial name
- WILLOW CCS (NCT04990791)
- Testing
- Aspirin 75mg, Aspirin 20mg, Rivaroxaban 2.5 mg
- Where
- United Kingdom
- Volunteers
- 48 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Angina Pectoris, Coronary Artery Disease
Effects of Integrated Treatment by Traditional Chinese and Western Medicine in Reducing Cardiovascular Events
Compared with standardized western medical drug therapy, this study is mainly about whether the combination of standardized western medical drug therapy and Chinese medical continued treatment, can further decrease the rate of…
- Conditions
- Angina Pectoris, Coronary Artery Disease, Coronary Disease, Heart Disease
- Trial name
- NCT01715376
- Where
- China
- Volunteers
- 1,042 people, healthy volunteers welcome
- Sponsor
- Changchun University of Chinese Medicine
Post Acute Coronary Syndrome, Myocardial Ischemia
Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome
The purpose of this study is to test the hypothesis that the inhibition of the renin-angiotensin-aldosterone system (RAAS) with the angiotensin receptor blocker valsartan or the renin antagonist aliskiren will improve ventricular…
- Trial name
- NCT00409578
- Testing
- Aliskiren 300 mg, Valsartan 320 mg, Aliskiren/valsartan 300/320 mg
- Where
- 11 sites in United States, Belgium and 9 more
- Volunteers
- 1,101 people
- Sponsor
- Novartis
ASCVD, NSTEMI
Telehealth Group Counseling and Preventive Care for Women
The purpose of this study is to utilize an innovative healthcare delivery strategy via telehealth group counseling sessions to improve engagement, adherence, and ultimately outcomes in female patients with atherosclerotic…
- Conditions
- ASCVD, NSTEMI, STEMI, Coronary Artery Disease
- Trial name
- NCT06404515
- Testing
- Telehealth Group Counseling
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Weill Medical College of Cornell University
Acute Coronary Syndrome, Myocardial Ischemia
Linking Cardiac Autonomic Dysfunction and InfLammation in Patients With Acute Coronary Syndromes
Subclinical inflammation plays a critical role in all stages of the atherosclerotic process, from the initiation of the fatty streaks to the development of plaque instability and rupture, causing myocardial ischemia and acute…
- Trial name
- CADILACS (NCT05756452)
- Testing
- Anamnesis and clinical evaluation
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Coronary Artery Stenoses, Stable Angina
e-BioMatrix 6 Month DAPT France
Prospective, multi-center observational study to be conducted in up to 30 French interventional cardiology centers. The purpose of this observational study is to capture, in French Centers, clinical data of the BioMatrix Flex™…
- Conditions
- Coronary Artery Stenoses, Stable Angina, Ischemia, NSTEMI - Non-ST Segment Elevation MI
- Trial name
- NCT03461484
- Volunteers
- 2,098 people
- Sponsor
- Biosensors Europe SA
Coronary Heart Disease
CTCA Prior to Invasive Angiography in Post-Bypass Patients (BYPASS CTCA 2)
The goal of this clinical trial is to evaluate whether a coronary computed tomography angiography (CTCA)-guided strategy can reduce the risk of death, heart attack, stroke, and hospital admissions in patients experiencing angina…
- Trial name
- NCT07165678
- Testing
- CTCA
- Where
- United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- Queen Mary University of London
Coronary Artery Disease, Ischemia
Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment (The EXACT Trial)
The primary purpose of this trial is to determine the safety of XC001 (AdVEGFXC1) in patients who suffer from angina caused by coronary artery disease and have no other treatment options.
- Conditions
- Coronary Artery Disease, Ischemia, Angina Refractory, Cardiovascular Diseases
- Trial name
- EXACT (NCT04125732)
- Testing
- AdVEGFXC1
- Where
- 16 sites in United States
- Volunteers
- 41 people
- Sponsor
- XyloCor Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.